Literature DB >> 19414584

Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.

Khaled Abduljalil1, Martina Kinzig, Jürgen Bulitta, Stefan Horkovics-Kovats, Fritz Sörgel, Michael Rodamer, Uwe Fuhr.   

Abstract

Clarithromycin decreases CYP3A4 activity and thus gradually inhibits its own metabolism as well as that of coadministered drugs. The aim of this study was to obtain an understanding of the time course of these changes. The plasma concentration-time profiles of clarithromycin and its active metabolite, 14(R)-hydroxy-clarithromycin, in 12 young healthy volunteers after oral administration of a clarithromycin suspension (500 mg twice a day [b.i.d.] for seven doses) were modeled by population pharmacokinetic analysis in the NONMEM program. The nonlinearity of clarithromycin metabolism was considered during model development, and the metabolite disposition kinetics were assumed to be linear. The absorption kinetics of clarithromycin were best described by a Weibull function model. The pharmacokinetics of clarithromycin and its 14(R)-hydroxyl metabolite were adequately described by a one-compartment model each for clarithromycin and its metabolite as well as an inhibition compartment that reflects the autoinhibition of clarithromycin metabolism. Up to 90% of the apparent total clarithromycin clearance (60 liters/h) was susceptible to reversible autoinhibition, depending on the concentration in the inhibition compartment. The proposed semimechanistic population pharmacokinetic model successfully described the autoinhibition of clarithromycin metabolism and may be used to adjust the doses of other drugs that are metabolized by CYP3A4 and that are coadministered with clarithromycin. Simulations showed that for the standard dose of 500 mg b.i.d., no further increase in the level of exposure occurs after approximately 48 h of treatment. For a 1,000-mg b.i.d. dose, the achievement of steady state is expected to take several days and to achieve a 3.6-fold higher level of clarithromycin exposure than the 500-mg b.i.d. dose. This evaluation provides a rationale for safer and more effective therapy with clarithromycin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414584      PMCID: PMC2704653          DOI: 10.1128/AAC.01193-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Absolute bioavailability of clarithromycin after oral administration in humans.

Authors:  S Y Chu; R Deaton; J Cavanaugh
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae.

Authors:  S J Martin; C G Garvin; C R McBurney; E G Sahloff
Journal:  J Antimicrob Chemother       Date:  2001-05       Impact factor: 5.790

3.  In vivo effect of clarithromycin on multiple cytochrome P450s.

Authors:  M A Bruce; S D Hall; B D Haehner-Daniels; J C Gorski
Journal:  Drug Metab Dispos       Date:  2001-07       Impact factor: 3.922

4.  Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.

Authors:  A D Rodrigues; E M Roberts; D J Mulford; Y Yao; D Ouellet
Journal:  Drug Metab Dispos       Date:  1997-05       Impact factor: 3.922

Review 5.  Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients.

Authors:  B J Anderson; A D McKee; N H Holford
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 6.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

7.  Improvement in the handling of drug-drug interactions.

Authors:  Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-01-03       Impact factor: 2.953

8.  Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.

Authors:  Hideki Ushiama; Hirotoshi Echizen; Shinobu Nachi; Akihiro Ohnishi
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

9.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

Review 10.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more
  8 in total

1.  Empirical models for fitting of oral concentration time curves with and without an intravenous reference.

Authors:  Michael Weiss
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-01       Impact factor: 2.745

2.  Rhabdomyolysis following a short course of clarythromycin.

Authors:  Anna M Schor; Ann Hellerstein
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

3.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

4.  Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.

Authors:  Jürgen B Bulitta; Olanrewaju O Okusanya; Alan Forrest; Sujata M Bhavnani; Kay Clark; J Gordon Still; Prabhavathi Fernandes; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

5.  A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.

Authors:  Firat Kaya; Jacqueline P Ernest; Katherine LoMauro; Martin Gengenbacher; Abdeldjalil Madani; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Jansy P Sarathy; Nadine Alvarez; Isaac Daudelin; Han Wang; Faye Lanni; Danielle M Weiner; Laura E Via; Clifton E Barry; Kenneth N Olivier; Thomas Dick; Brendan K Podell; Radojka M Savic; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2022-01-31       Impact factor: 5.938

6.  Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.

Authors:  Amit Desai; Laura Kovanda; Donna Kowalski; Qiaoyang Lu; Robert Townsend; Peter L Bonate
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 7.  Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.

Authors:  Bryan J Donald; Salim Surani; Harmeet S Deol; Uche J Mbadugha; George Udeani
Journal:  Drug Des Devel Ther       Date:  2017-12-13       Impact factor: 4.162

8.  Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects.

Authors:  Woo Yul Lee; EunSil Oh; Mengqi Cui; Choon Ok Kim; Yeji Lim; Hunam Kim; Hyeonsoo Park; Sukyong Yoon; Min Soo Park; Taegon Hong
Journal:  Transl Clin Pharmacol       Date:  2020-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.